# Exonate

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/exonate

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.exonate.com
- Total disclosed funding: $3.8M
- Latest round: Angel (Jul 20, 2016)
- Investors on record: 10

## About

Exonate Limited specializes in developing innovative therapies for retinal vascular diseases. Their lead product, EXN407, targets conditions like diabetic retinopathy and aims to address significant unmet medical needs in the biopharmaceutical sector.Exonate Limited is focused on developing therapies for retinal vascular diseases. Founded in 2013, the company is headquartered in Cambridge, UK. Lucy Donaldson is the founder, and she has a history of involvement in the biopharmaceutical sector. Exonate has completed 6 deals, with the most recent being on January 3, 2019, when they raised GBP 1.5 million in venture funding, marking the total amount raised at GBP 1.5 million.Exonate's primary product offering is EXN407, aimed at becoming the first topical therapy for retinal vascular diseases, specifically for diabetic retinopathy and diabetic macular oedema. This product works by modulating alternative mRNA splicing to address pathological blood vessel formation contributing to these diseases. The company emphasizes developing small molecule drugs to meet high unmet medical needs in biopharmaceuticals, targeting patient populations affected by severe vision loss and engaging healthcare providers for treatment.Exonate's revenue model relies on partnerships and potential licensing agreements for EXN407. Collaborative efforts with healthcare providers and pharmaceutical partners involve supplying innovative therapies for clinical use. While specific pricing structures have not been disclosed, revenue is anticipated to grow as EXN407 advances through clinical trials, with commercial partnerships expected to drive future sales.Following the GBP 1.5 million funding round in January 2019, Exonate plans to utilize these resources to further develop EXN407 and advance its clinical trials, targeting an expansion into new markets for retinal disease therapies. Specific geographic regions for expansion have not been disclosed, but the company's strategy includes scaling operations to capture market segments for treatments addressing retinal vascular diseases.

## Funding rounds

- Angel, Jul 20, 2016, $1.9M — Uniseed, Parkwalk Advisors, ACF Investors, Wren Capital, Martlet Capital, O2h Ventures
- Angel, Apr 2, 2015, $1.2M — ACF Investors
- Angel, Apr 4, 2014, $0.7M — Longview Innovation, Fusion IP, University of Nottingham, Nottingham Angels Network

## Investors

- Longview Innovation (https://capitalatlas.ai/funds/longview-innovation) — Angel
- Fusion IP — Angel
- University of Nottingham — Angel
- Nottingham Angels Network — Angel
- ACF Investors (https://capitalatlas.ai/funds/acf-investors) — Angel
- Uniseed (https://capitalatlas.ai/funds/uniseed) — Angel
- Parkwalk Advisors (https://capitalatlas.ai/funds/parkwalk-advisors) — Angel
- Wren Capital (https://capitalatlas.ai/funds/wren-capital) — Angel
- Martlet Capital (https://capitalatlas.ai/funds/martlet-capital) — Angel
- O2h Ventures (https://capitalatlas.ai/funds/o2h-ventures) — Angel